Therefore, RAS/ERK activation does not drive oncogenic ETS expression in prostate cancer cell lines, however in at least one context (ERG in RWPE) an oncogenic ETS could induce the phosphorylation of both AKT and, to a lesser degree, ERK. This evidence concerns the gene AKT1 and prostate carcinoma.